Consequences of hypoxia-reoxygenation phenomena in patients with obstructive sleep apnea syndrome

Tansu Ulukavak Ciftci, Oguz Kokturk, Senay Demirtas, ÖZlem Gülbahtar, Neslihan Bukan

From the *Sleep Disorders Center, Gazi University Faculty of Medicine, Ankara, †Department of Biochemistry, Faculty of Medicine, Gazi University, Ankara, Turkey

Correspondence: Dr. Tansu Ulukavak Ciftci · Sancak Mah, 525 Sok No: 17/7 Çankaya, Ankara, Turkey · T: +90-312-202-6119 F: +90-312-212-9019 · tansu.ciftci@gazi.edu.tr · Accepted: 16 October 2010

Ann Saudi Med 2011: 31(1): 14-18

PMID: ****  DOI: 10.4103/0256-4947.75772

**BACKGROUND AND OBJECTIVES:** Obstructive sleep apnea syndrome (OSAS) is a common disorder characterized by numerous episodes of absence of respiratory flow during sleep, which can be followed by a decrease in $\text{Sa}_2$, which is rapidly normalized when ventilation resumes. We hypothesize that this hypoxia–reoxygenation phenomena may affect the generation of vascular endothelial growth factor (VEGF), erythropoietin (EPO), endothelin-1 (ENDO-1), and inducible nitric oxide synthase (iNOS).

**DESIGN AND SETTING:** Prospective, patients referred to sleep disorders center.

**PATIENTS AND METHODS:** The presence and severity of OSAS were determined using the standard overnight polysomnography. Diagnosis of OSAS was made when the apnea-hypopnea index (AHI) was $\geq 15$, independent of the appearance of symptoms. Serum levels of VEGF, EPO, ENDO-1, and nitrite–nitrate were measured after overnight fasting in 69 patients with OSAS and in 17 healthy control subjects. Serum levels of VEGF and nitrite-nitrate were measured again after 12 weeks of treatment with continuous positive airway pressure (CPAP) in OSAS patients.

**RESULTS:** Serum VEGF levels were found to be significantly higher and nitrite–nitrate levels were found to be significantly lower in OSAS patients than in controls ($P=.003, .008$, respectively), but no differences in EPO and ENDO-1 levels were found between the groups. We demonstrated that in OSAS patients, the serum VEGF levels were decreased and nitrate levels were increased after 12 weeks of CPAP treatment ($P=.001, .002$, respectively).

**CONCLUSION:** According to our data, it is likely that hypoxia–reoxygenation phenomena affect the VEGF and nitrite–nitrate levels, which may be pathogenic factors in generating cardiovascular complications in OSAS.

Obstructive sleep apnea syndrome (OSAS) is characterized by repeated episodes of upper airway obstruction during sleep, associated with increasing respiratory efforts, intermittent arterial oxygen desaturation, systemic and pulmonary arterial blood pressure surges, and sleep disruption. OSAS is highly prevalent disease in the population, affecting $\geq 4\%$ of males and $2\%$ of females. The typical OSAS patient is male, middle-aged, and obese. Obesity unfavorably affects respiratory function and may promote the collapse of the upper airway during sleep in addition, when body weight increases, the frequency of respiratory events during sleep also increases.

According to recent studies, untreated moderate-to-severe OSAS was associated with increased rates of nonfatal cardiovascular events after a relatively short follow-up. At least four longitudinal studies have confirmed increased cardiovascular morbidity in OSAS patients. Besides decreasing lung function, obesity increases cardiovascular risk, making it hard to assess the independent role of OSAS on cardiovascular morbidity and mortality. The interrelationships between obesity and OSAS are complex and possibly bidirectional, and some authors believe that OSAS should be considered as one manifestation of the metabolic syndrome. The basic mechanisms involved in the increased cardiovascular risk of OSAS remain unclear. In fact, several studies support the existence of oxidative stress and endothelial dysfunction in OSAS, and several authors have suggested a possible involvement of the latter in the
pathogenesis of cardiovascular disease in these patients. OSAS is characterized by the occurrence of numerous episodes of apneas during sleep, which can be followed by a decrease in $S_{\text{a}}O_2$, that is rapidly normalized when ventilation resumes. We hypothesize that these hypoxia–reoxygenation phenomena may effect the generation of vascular endothelial growth factor (VEGF), erythropoietin (EPO), endothelin-1 (ENDO-1), and inducible nitric oxide synthase (iNOS). To date, no study has evaluated more than two parameters related to oxidative stress in OSAS patients comparing to a control group of similar age and body mass index.

**PATIENTS AND METHODS**

We enrolled newly diagnosed cases with OSAS and age- and body mass index-matched control subjects. Subjects were recruited from patients referred to the Sleep Disorders Center of Gazi University Faculty of Medicine for suspected sleep apnea. The study was approved by the Institutional Ethics Committee, and conducted in accordance with the guidelines of the Declaration of Helsinki. The subjects were examined with polysomnography (PSG) and classified as controls according to data of the apnea-hypopnea index (AHI). All patients with OSAS were also diagnosed with PSG. Before enrollment, all subjects gave written informed consent to participation.

Overnight PSG was performed in all patients by a computerized system (Somnostar alpha; Sensormedics, USA) and included the following variables: electrooculogram (2 channels), electroencephalogram (4 channels), electromyogram of submental muscles (2 channels), electromyogram of the anterior tibialis muscle of both legs (2 channels); electrocardiogram, and airflow (with a nasal cannula). Chest and abdominal efforts (2 channels) were recorded using inductive plethysmography, arterial oxyhemoglobin saturation ($S_{\text{a}}O_2$; 1 channel) by pulse oximetry with a finger probe. The recordings were conducted at a paper speed of 10 mm/s, and sleep stage was scored according to the standard criteria of Rechtschaffen and Kales. Arousals were scored according to accepted definitions. The AHI was obtained by dividing the total number of apneas and hypopneas by the total sleep time. Apneas were defined as complete cessation of airflow ≥10 seconds. Hypopneas were defined as a reduction of >50% in one of three respiratory signals, airflow signal or either respiratory or abdominal signals of respiratory inductance plethysmography, with an associated decrease of ≥3 % in oxygen saturation or an arousal. According to the recently updated International Classification of Sleep Disorders published by the American Academy of Sleep Medicine, a diagnosis of OSAS was made if the AHI is ≥15, independent of occurrence of symptoms, or whenever an AHI >5 is associated with any of the following: (1) sleep attacks or excessive daytime sleepiness, unrefreshing sleep, fatigue or (2) insomnia, or (3) witnessed heavy snoring and/or breathing pauses referred by the partner. In the control subjects, OSAS was excluded by a negative history of sleep-related symptoms (snoring, witnessed apneas, and excessive daytime sleepiness) and with an AHI <5 at overnight PSG. Patients with sleep disorders, except OSAS, such as upper airway resistance syndrome, periodic leg movement syndrome or narcolepsy, were excluded.

During the first night, a diagnostic study was performed. After confirming the diagnosis of OSAS, continuous positive airwave pressure (CPAP) therapy was given to all patients during the second night (REM Star; Respironics, Murrysville, PA, USA) during 12 weeks. Compliance with treatment was checked by the timer built up in the CPAP device. A priori, good compliance for post-treatment evaluation was defined as the mean usage of CPAP > 4 hours per night for 5 days of the week. According to these criteria, 20 patients were excluded from the follow-up analysis. Diurnal $S_{\text{a}}O_2$ (before wake), minimum nocturnal $S_{\text{a}}O_2$ ($S_{\text{a}}O_2$ min), mean nocturnal $S_{\text{a}}O_2$ ($S_{\text{a}}O_2$ mean), and time spent (percent of the recording time) with $S_{\text{a}}O_2$ less than 90% (desaturation percent) were recorded for all cases. An $S_{\text{a}}O_2$ value <90% was defined as hypoxia.

Serum levels of VEGF, EPO, ENDO-1, and nitrite–nitrate were measured after overnight fasting. Serum VEGF levels were measured with a solid phase sandwich enzyme linked-immunosorbent assay (ELISA) using a human VEGF kit (Biosource International, Inc., USA). The minimum detectable dose of VEGF is 5 pg/mL with this assay protocol. Endothelin-1 levels were determined using immunometric EIA (enzyme immunometric assay) kit (Cayman Chemical, Michigan, USA) that permits endothelin measurements within the range of 0-250 pg/mL, typically with a limit a detection of 1.5 pg/mL. inter- and intra-assay CVs are <10?.

Nitric oxide (NO) gas has a short plasma half-life of only a few seconds, and is difficult to measure. More feasible is the measurement of the more stable derivatives of NO (nitrite and nitrate) in biological fluids. Nitrite and nitrate concentrations not only depend on endothelial NO formation, but also other aspects of NO metabolism such as distribution in various body compartments and the rate of elimination by the kidneys. Nevertheless, nitrite and nitrate levels have been suggested as the most appropriate measure of overall
NO production. Nitrate and nitrite levels were determined using nitrate/nitrite colorimetric assay kit (Cayman Chemical, Michigan, USA). The first step was the conversion of nitrate to nitrite using nitrate reductase. In the second step, nitrite concentrations were measured by the Griess reaction. Means and standard errors of measurement (SEM) were determined for continuous variables and percentage for categorical variables. The significance of differences between the two groups was analyzed with the Mann–Whitney U-test. The correlation was analyzed with the Pearson correlation coefficient. All statistical analyses were carried out using statistical software (SPSS, version 11.0 for Windows; SPSS Inc; Chicago, IL). Differences were considered significant at \( P < .05 \).

**RESULTS**

After 186 subjects underwent PSG, 89 were considered to have OSAS (AHI >15). Twenty patients were excluded from the follow-up analysis because of poor compliance. Sixty-nine patients were included in the OSAS group. Seventeen subjects without OSAS (AHI <5) were enrolled as control subjects. Table 1 shows the main clinical characteristics of patients with OSAS and healthy controls. Table 2 shows the values of the different biological markers. Serum VEGF levels were significantly higher and nitrite–nitrate levels were significantly lower in OSAS patients than in controls (\( P = .003, P = .008 \), respectively), but no differences in EP and ENDO-1 levels were found between the groups. In OSAS patients, serum VEGF levels were decreased and nitrate levels were increased after 12 weeks of CPAP treatment (\( P = .001, P = .002 \), respectively) (Table 3). VEGF levels were significantly and negatively correlated with SaO\(_2\) (wake), SaO\(_2\) (min), SaO\(_2\) (mean), and desaturation percent in all cases (\( n = 186 \)) (\( P = .01, P = .001, P = .003, P = .04 \), respectively) and in OSAS patients (\( n = 69 \)) (\( P = .03, P = .001, P = .03, P = .03 \), respectively). There was no significant correlation between other parameters and SaO\(_2\) both in OSAS patients and all cases.

**DISCUSSION**

Reperfusion–reoxygenation injury refers to the damage that occurs as a result of restoration of the blood circulation to an ischemic or hypoxic tissue. Although several mechanisms inflict this damage, it is mainly attributed to free radical production during reoxygengation. Hypoxia/reoxygenation induces complex metabolic and molecular changes including: (1) changes in energy metabolism, (2) alterations in gene expression, and (3) induction of cell surface molecules. All are intercalated with altered free radical flux, which affects NO bioavailability as well.

NO, an intracellular signaling molecule as well as a free radical, is affected by hypoxia. NO is the main vasodilating substance released from the endothelium. Deficiency of NO has been implicated in the pathogenesis of cardiovascular disease. In our study, plasma levels of nitrate were found to be markedly reduced in a group of 69 untreated patients with OSAS. After 12 weeks of CPAP therapy, nitrate levels increased in this group. Ip and colleagues reported suppression of circulating NO derivatives in OSAS, rapidly reversible upon onset of nasal continuous positive airway pressure (nCPAP) therapy. Ip and associates failed to mention some possibilities. First, as oxygen is a cosubstrate of NO synthase (NOS), OSA-related nocturnal desaturation might result in depressed synthesis of NO. Second, nighttime hypoxia might suppress the transcription of the endothelial NOS gene and

| Table 1. The main clinical characteristics of patients with OSAS and healthy controls. |
|---------------------------------|-----------------|------------------|------|
| **Sex (M/F)**                   | OSAS Patients   | Control Group    | \( P \) |
| Sex (M/F)                       | 49/20           | 11/6             | .58  |
| Age (mean ± SD)                 | 53.27 (11.38)   | 51.5 (10.5)      | .33  |
| Body mass index                 | 30.9 (6.2)      | 29.1 (4.6)       | .17  |
| Apnea-hyponea index             | 48.4 (30.4)     | 1.89 (1.1)       | <.001|
| SaO\(_2\) (wake)                | 94.5 (1.8)      | 95.3 (1.5)       | .17  |
| SaO\(_2\) (min)                 | 73.9 (9.5)      | 87.6 (3.1)       | <.001|
| SaO\(_2\) (mean)                | 88.3 (3.9)      | 92.6 (2.1)       | .001 |
| Desaturation percent            | 38.02 (35.67)   | 12.75 (26.8)     | <.001|

Diurnal SaO\(_2\) (SaO\(_2\) wake), minimum nocturnal SaO\(_2\) (SaO\(_2\) min), mean nocturnal SaO\(_2\) (SaO\(_2\) mean), and time spent (percent of the recording time) with SaO\(_2\) <90% (desaturation percent).
hypoxia-redoxygenation in osa

the stability of its mRNA as suggested by cell culture experiments performed under hypoxic conditions. Third, it has been demonstrated that NOS inhibitors are elevated in OSAS and thus, might also contribute to lowered nitrite/nitrate levels. Finally, it is quite possible that NO is scavenged by free oxygen radicals generated under conditions of hypoxia–reoxygenation by circulating neutrophils. Ohike et al’s findings suggest that nCPAP reduces the concentration of asymmetric NG–NG-dimethylarginine (ADMA), which is an endogenous inhibitor of endothelial NO synthesis, thereby enhancing NO production and leading to an improvement of endothelium-dependent vasodilation. Hypoxia induces the activation of the adaptive pathway mediated by upregulation of the transcription factor hypoxia-inducible factor (HIF-1). There is evidence of HIF-1 dependent gene activation in OSAS as indicated by increased levels of VEGF.

VEGF is a vasodilator that induces the proliferation of endothelial cells, increases vascular permeability, and causes greater production of NO and prostacyclin. Hypoxia is believed to stimulate the production of VEGF. Investigators have sought to implicate VEGF as part of the mechanism by which OSAS results in greater incidence of cardiovascular disease. Our results showed that the concentrations of VEGF were significantly higher in OSAS patients than in healthy controls and were decreased after 12 weeks of CPAP treatment. Many, but not all studies, have found elevated VEGF levels in subjects with OSAS. In study of Phillips et al, 1 week of CPAP withdrawal was associated with a return of OSAS and marked increase in sympathetic activity with out a concomitant elevation of VEGF. In contrast, VEGF levels were found elevated in OSAS in some studies. Apnea-associated hypoxia is also likely to play a significant role in the increased levels of VEGF found in OSAS, because levels have been found to rapidly decrease after one night of oxygen administration. According to the importance of hypoxia for VEGF levels, our study showed that the mean value of time spent with SaO2 less than 90% (desaturation percent) was higher in OSAS patients than that of controls, VEGF levels were significantly and negatively correlated with SaO2 (wake), SaO2 (min), SaO2 (mean), and desaturation percent. Erythropoietin regulates the red blood cell mass. Sustained cellular hypoxia is associated with the activation of a ubiquitous transcriptionally initiated response mediated by the transcription factor HIF-1. HIF-1 is activated in sustained hypoxia through a well-defined mechanism, resulting in increased expression of a number of genes encoding proteins such as EPO. Previous reports have indicated that there is activation of the HIF-1 pathway in OSAS. In our study, there was no difference in EPO levels between the groups. EPO levels have been reported as increased in OSAS, but this increase was observed only in patients with severe disease and a higher body mass index. A possible explanation for these different findings is that patients with severe OSAS may be exposed to a sufficient cumulative period of sustained hypoxia during sleep to activate the HIF-1-dependent pathway.

Endothelin-1 (ET-1) is a potent vasoconstrictive and mitogenic peptide. Recently, evidence has emerged suggesting a role for an enhancer of chemoreceptor activity, endothelin (ET), as a mediator of acclimatization. ET is a 21-amino acid peptide found in endothelium and in type 1 cells (glomerus cells) in the carotid bodies. Chen and colleagues have presented evidence, based on reverse transcriptase polymerase chain reaction, that continuous hypoxia increases expression of the ET receptor and of preproendothelin. An association between ENDO-1 and OSAS could be assumed but in our study there was no difference in ET levels between the groups. Similarly, Diefenbach and colleagues showed that ET plasma levels of untreated OSAS patients and of patients treated with nasal CPAP were not elevated compared with controls. Conversely, Gjorup et al studied the OSAS patients and control subjects during the nighttime with serial determinations of ET in plasma and showed that OSAS patients had a higher plasma level of ET than healthy controls and the mean nocturnal level of ET correlated significantly to

Table 2. Serum VEGF, nitrite-nitrate, EPO, and ENDO-1 levels in OSAS patients and in control group.

|                | OSAS Group | Control Group | P |
|----------------|------------|---------------|---|
| VEGF           | 168.16 (3.7) | 89.1 (11.4)   | .003 |
| Nitrite-nitrate | 0.5 (0.5)  | 0.81 (0.7)    | .008 |
| EPO            | 10.8 (6.0)  | 9.7 (5.1)     | .5  |
| ENDO-1         | 36.7 (5.4)  | 37.7 (5.4)    | .2  |

Table 3. Serum VEGF and nitrite-nitrate levels in OSAS patients at date of diagnosis and after 12 weeks of CPAP treatment.

|                | Before CPAP | After CPAP | P   |
|----------------|-------------|------------|-----|
| VEGF           | 168.16 (3.7) | 106.05 (8.5) | .001 |
| Nitrite-nitrate | 0.5 (0.5)  | 0.86 (0.4)  | .002 |

VEGF: vascular endothelial growth factor, EPO: erythropoietin, ENDO-1: endothelin-1.
REFERENCES

1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-5.
2. Ferretti A, Giampiccolo P, Cavalli A, Milic-Emili J, Tantucci C. Expiratory flow limitation and orthopnea in massively obese subjects. Chest 2001;119:1401-8.
3. Newman AB, Foster G, Givelber R, Nieto FJ, Redline S, Young T. Progression and regression of sleep-disordered breathing with changes in weight: The Sleep Heart Health Study. Arch Intern Med 2005;165:2408-13.
4. Partinen M, Guilleminault C. Daytime sleepiness and vascular morbidity at seven year follow-up in obstructive sleep apnea patients. Chest 1990;97:27-32.
5. Pendlebury ST, Pepin JL, Veale D, Levy P. Natural evolution of moderate sleep apnea syndrome: Significant progression over a mean of 17 months. Thorax 1997;52:872-8.
6. Zanninelli A, Fariello R, Boni E, Corda L, Alciandri C, Grassi V. Snoring and risk of cardiovascular disease. Int J Cardiol 1991;32:347-51.
7. Doherty LS, Kiely JL, Swan V, McNicholas WT. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest 2005;127:2076-84.
8. Punjabi NM, Polotsky VY. Disorders of glucose metabolism in sleep apnea. J Appl Physiol 2005;99:1998-2007.
9. Vgontzas AN, Bixler ED, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005;9:211-24.
10. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques, and scoring system for sleep stages in human subjects. Los Angeles, CA: Brain Information Service, VCLA; 1968.
11. EEG arousals: Scoring rules and examples: A preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992;15:173-84.
12. The report of an American Academy of Sleep Medicine Task Force. Sleep-Related Breathing Disorders in Adults: Recommendations for Syndrome Definition and Measurement Techniques in Clinical Research. Sleep 1999;22:967-89.
13. American Academy of Sleep Medicine (AASM). International Classification of Sleep Disorders. Westchester, United States: AASM; 2005.
14. Neufeld G, Cohen T, Gengrinovitch S, Pottorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
15. Aubin P, Le Brun G, Moldovan F, Villette JM, Créminon C, Dumas J, et al. Sandwich-type enzyme immunoassay for big endothelin-I in plasma: Concentrations in healthy human subjects unaffected by sex or posture. Clin Chem 1997;43:84-70.
16. Vinikka L. Nitric oxide as a challenge for the clinical chemistry laboratory. Scand J Clin Lab Invest 1996;56:377-81.
17. Moncada S, The 1991 Ulf von Euler Lecture. The L-arginine: Nitric oxide pathway. Acta Physiol Scand 1992;145:201-27.
18. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1993;36:97-104.
19. Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular diseases. Prog Cardiovasc Dis 1995;38:105-28.
20. Ip MS, Lam B, Chan LY, Zheng L, Tsang KW, Fung PC, et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Resp Care Med 2000;162:2166-71.
21. Ohike Y, Kozaki K, Iijima K, Eto M, Kojima T, Ogita E, et al. Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure. Circ J 2005;69:221-6.
22. Gozal D, Lipton AJ, Jones KL. Circulating vascular endothelial growth factor level: A potential mechanism of systemic inflammation in sleep-disordered breathing. Sleep 2003;26:5965.
23. Phillips CI, Yang Q, Williams A, Roth M, Yee BJ, Hedner JA, et al. The effect of short-term withdrawal from continuous positive airway pressure therapy on sympathetic activity and markers of vascular inflammation in subjects with obstructive sleep apnea. J Sleep Res 2007;16:217-25.
24. Gozal D, Lipton AJ, Jones KL. Circulating vascular endothelial growth factor levels in patients with obstructive sleep apnea. Sleep 2002;25:59-65.
25. Teramoto S, Kume H, Yamamoto H. Effects of oxygen administration on the circulating vascular endothelial growth factor (VEGF) levels in patients with sleep apnea syndrome. Intem Med 2003;42:681-5.
26. Winnicki M, Shamsuzzaman A, Lanfranchi P, Accurso V, Elson E, Davison D, et al. Erythropoietin and obstructive sleep apnea. Am J Hypertens 2004;17:783-6.
27. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005;112:2660-7.
28. Chen J, He L, Dinger B, Stensaaa LS, Rolle of endothelin and endothelin A-type receptor in adaptation of the carotid body to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2001;282:L134-23.
29. Diefenbach K, Kretschmer K, Bauer S, Malzahn U, Perozzi T, Roots I, et al. Endothelin-1 gene variant Lys198Asn and plasma endothelin level in obstructive sleep apnea. Sleep Med 2008;9:62-8.
30. Gjorup PH, Sadauskiene L, Wessels J, Nyvad O, Strunge B, Pedersen EB. Abnormally increased endothelin-1 in plasma during the night in obstructive sleep apnea. Am J Hypertens 2007;20:44-52.